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Abstract
Background/aims: The molecular mechanisms leading
to loss in muscle force during an acute exacerbation
in COPD patients are unknown. A cross-sectional
study was designed to compare the gene expression
profile of the vastus lateralis muscle in patients with
an acute COPD exacerbation and in stable COPD
patients. Methods: Muscle biopsies were taken in 9
COPD patients with an exacerbation on day 4 of
hospitalization and in 15 stable COPD patients. Micro-
array was performed on an UniSet Human 20K
Bioarray. Results: Gene Ontology and Gene Set
Enrichment Analysis of the microarray data revealed
enrichment of 1) the ubiquitin-dependent protein
catabolism, the induction of apoptosis and anti-
apoptosis and the response to reactive oxygen
species in the upregulated transcripts, and 2) the
aspartate catabolism and the mitochondrial
respiratory chain in the downregulated transcripts.
Real Time PCR data confirmed 1) increased
expression of MuRF1 and MAFbx, markers of the
ubiquitin dependent catabolism pathway, and 2)
decreased expression levels of COX6C, a marker of
mitochondrial respiration. Conclusions: The present
study suggests that multiple pathways leading to
muscle atrophy and mitochondrial dysfunction are
altered in the muscle during an acute exacerbation.
Strategies limiting the loss of muscle function during
an acute exacerbation need to be developed.
Introduction
Chronic obstructive pulmonary disease (COPD) is
a slowly progressing disease characterized by airflow
obstruction and chronic inflammation [1]. COPD is also
associated with several systemic co-morbidities, such as
osteoporosis, increased risk of cardiovascular diseases
and skeletal muscle wasting [2]. Skeletal muscle
weakness contributes to exercise intolerance and impaired
health-related quality of life [3]. Skeletal muscle function
is critical to survival and predicts the mortality risk in
patients with COPD [4]. Disuse due to sedentary lifestyle
[5], the use of corticosteroids [6], the presence of systemic
inflammation [7] and/or oxidative stress [8] further
contribute to the development and the progression of
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muscle weakness in COPD.
The mechanisms underlying the wasting process in
this disease are not known. Recently, the mRNA
expression profile of the quadriceps muscle in stable
COPD patients identified several genes that were distinctly
regulated compared to control subjects [9, 10]. Among
others, genes involved in protein degradation and synthesis,
energy production, muscle contraction and regeneration
were selectively expressed in the quadriceps muscle of
the stable COPD patients. These studies provided for
the first time evidence for impaired gene expression in
the muscle of stable COPD patients that may contribute
to muscle dysfunction described in this population.
In COPD patients, repeated exacerbations represent
a common feature of the disease. Exacerbations exert
serious detrimental effects on the patient and lead to a
significant increase in health care resource utilization.
Exacerbations are associated with accelerated decline in
lung function [11], further impairment of quality of life
[12] and increased mortality risk [13]. In addition,
exacerbations result in a further decline in skeletal muscle
force. This loss of muscle function is rapid but recovery
is slow and partial [14]. This means that in patients with
frequent exacerbations, muscle weakness probably
accumulates since loss of muscle function occurring
during an exacerbation may take place during recovery
phase.
As for stable COPD patients, the mechanisms
triggering muscle weakness during exacerbations are not
known. It is now accepted that during acute exacerbation,
enhanced systemic inflammation is present in the lung
and the systemic circulation and this may affect several
systems. Local expression of inflammatory markers such
as IL-6, IL-8 and TNF-α was, however, not present in
the skeletal muscle of these patients [15] whereas
expression levels of the anabolic markers MyoD and
IGF-I were decreased in their muscle [15]. MyoD
expression levels showed to be positively related to
muscle force [15]. These data suggested a prominent
role for local rather than systemic regulating mechanisms
in the occurrence of skeletal muscle weakness during an
acute COPD exacerbation.
Knowledge on the mechanisms involved in the loss
of muscle function during an acute exacerbation may be
helpful to develop appropriate strategies to better preserve
muscle function in these patients. This is, indeed, clinically
relevant knowing that recovery of muscle force is
particularly slow as it does not return to values seen in
stable COPD patients even three months after exacerba-
tion. In order to unravel the potential molecular events
Table 1. Characteristics of the population included in the
microarray screening. Data represent values on day 3 of
hospitalization, unless specified otherwise. Values are
expressed as means and standard deviation. N=number of
patients per group; BMI=body mass index; CRP=C-reactive
protein at hospital admission for the patients with an acute
exacerbation; FEV1=forced expiratory volume in the first second;
FVC=forced vital capacity; PaO2 and PaCO2=arterial oxygen
and carbon dioxide tension, PImax=maximal inspiratory mouth
pressure; QF=quadriceps force; %pred=percentage of
predicted value; *p<0.05.
Table 2. Characteristics of the population included in the
PCR experiment. Values are expressed as means and standard
deviation. N=number of patients per group; BMI=body mass
index; CRP=C-reactive protein at hospital admission for the
patients with an acute exacerbation; FEV1=forced expiratory
volume in the first second; FVC=forced vital capacity; PaO2
and PaCO2=arterial oxygen and carbon dioxide tension,
PImax=maximal inspiratory mouth pressure; QF=quadriceps force;
%pred=percentage of predicted value;  *p<0.05.
occurring in the muscle during an acute exacerbation, a
cross-sectional study was performed to compare the gene
expression profile of the vastus lateralis muscle in COPD
patients with an acute exacerbation and in stable COPD
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patients. We hypothetized that the investigation of the
mRNA expression profile of the quadriceps muscle may
be a useful screening tool to identify key pathways
involved in the loss of muscle function seen in COPD
patients during an acute exacerbation. These data may
lead to relevant issues to prevent or minimize further




First, a microarray screening was performed on the vastus
lateralis biopsy obtained from 4 COPD patients with an acute
exacerbation and 5 stable COPD patients. After completing the
whole data analysis of the micro-array screening, real time PCR
analysis of key genes was subsequently performed on 9 COPD
patients with an acute exacerbation and 13 stable COPD
patients. Eight out of the 9 COPD patients with acute
exacerbation and 8 out of the 15 stable COPD patients took
part in a previous study [15].
Patient population
Nine male COPD patients (forced expiratory volume in
the first second/forced vital capacity, FEV1/FVC<70%)
hospitalized for an acute exacerbation were compared to 15
clinically stable male COPD patients visiting the outpatient
clinic (FEV1/FVC<70%, no hospitalizations for acute
exacerbations within 1 year before testing, no participation in
training programs). They were matched for age, FEV1 and lung
function. An acute COPD exacerbation was defined as an
increase in symptoms of dyspnoea, sputum volume and
purulence and cough frequency for at least 48 hours. The
decision for hospital admission was made by the attending
chest physician present in the emergency room. Hospitalized
patients received 32mg/day oral methylprednisolone for 1 week,
followed by 24mg/day for 4 days and a subsequent decrease
of 4mg/week. On day 3 of hospitalization, pulmonary function,
maximal inspiratory mouth pressure, and quadriceps peak torque
were measured in all hospitalized patients. On day 4 of
hospitalization, percutaneous Bergström needle biopsies were
taken from the vastus lateralis muscle. All stable COPD patients
performed the aforementioned tests on 2 separate days in an
outpatient setting and vastus lateralis biopsies were taken.
Characteristics and physiological data of the population are
summarized in table 1 for the micro-array screening and in table
2 for the real time PCR experiment. All participants gave oral
and written informed consent to participate in the present study.
This study was approved by the Ethics Committee of the
University Hospitals Leuven.
Protocol
RNA isolation.Total RNA from the vastus lateralis muscle
was isolated using the Trizol method according to the
manufacturer’s protocol (Invitrogen, Merelbeke, Belgium).
Table 3. Sequence of primers used for the real time PCR
experiments. F: forward primer; R: reverse primer.
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Microarray data acquisition and preprocessing. Total
RNA was hybrized to a CodeLink UniSet Human 20K Bioarray
containing 20,000 human transcripts (Amersham Biosciences,
Diegem, Belgium) according to the manufacturer’s protocol at
the VIB MicroArray Facility (MAF, Leuven, Belgium). In brief,
biotin-labelled cRNA was synthesized by in vitro transcription
and quality checked with the Nanodrop. Ten µg of biotin-
labelled cRNA was fragmented and hybridized on the microarray
slides and subsequently scanned with an Agilent Scanner. Gene
expression was measured with the Codelink Expression
Analysis software. All primary microarray data has been
submitted in GEO under accession number GSE10828.
Microarray data analysis. Genemaths XT (Applied
Maths, Belgium) was used for the analysis of the microarray
data. Each microarray data file was background corrected and
intensity values less than 1 were excluded from further analysis.
Expression values were log2 transformed and quantiles
normalized.
Because alterations in gene expression might manifest at
the level of biological pathways or co-regulated gene sets rather
than individual genes [16], gene ontology analysis and gene
set enrichment analysis were used to analyze the microarray
data.
The gene ontology project classifies genes into a
hierarchy placing gene products with similar functions together.
Because gene ontology is hierarchical, a gene that is in one
category is automatically part of its parent classifications. Three
structured controlled vocabularies (ontologies) describe gene
products in terms of their associated biological processes,
cellular components and molecular functions. The web-based
applications GeneTrail [17] and DAVID (Database for
annotation, visualization and integrated discovery) [18, 19] were
used to analyze gene ontology enrichments in the differentially
expressed transcripts. Transcripts with a p<0.05 were
considered as differentially expressed and used as input for
Ontology Analysis.
The gene set enrichment analysis (GSEA) represents a
method of ranking pathways, or more generally gene sets, in
terms of coupling (e.g. causing or being caused by) to a
biological condition [16]. In contrast to Ontology analysis, the
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GSEA algorithm is based on the usage of all available gene
expression data. Data permutation is used to adjust for multiple
testing. Gene Sets with a p<0.05 and a False Discovery Rate
< 25%, cut off values as previously recommended [16], were
assumed to be significantly enriched.
Table 4. Top 25 of the most highly up-regulated genes between COPD patients with acute
exacerbation vs stable COPD patients.
Table 5. Top 25 of the most highly down-regulated genes between COPD patients with acute
exacerbation vs stable COPD patients.
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Finally, multidimensional scaling and principal component
analysis were used as qualitative methodology to characterize
the behavior of hospitalized and stable COPD patients. The
analysis is based on the set genes differentially expressed
between hospitalized and stable COPD patients.
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Table 6. Gene Ontology enrichment in vastus lateralis of hospitalized vs. stable
COPD patients. See text for details.
Table 7. GSEA analysis showing enriched pathways
in the vastus lateralis muscle of hospitalized compared
to stable COPD patients. See text for details. FDR =
False Discovery Rate.
Quantitative real time polymerase chain reaction
validation. First-strand cDNA was generated by reverse
transcription using random primers and the Super-ScriptTM II
kit (Invitrogen, Merelbeke, Belgium) according to the
manufacturer’s instructions. Amplification with primers (Table
3) was performed on an ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) using the
Platinum SYBR Green qPCR SuperMix UDG kit (Invitrogen).
Copy numbers of unknown samples were calculated from
plasmid cDNA standards. Data from each gene was expressed
as copy number of 18S.
Statistical and Expression Analysis
Unpaired t-test was used to assess differences between
patient characteristics. Data were expressed as mean and
standard deviation.
For the microarray, statistical analysis was done with the
Welsh t-test and corrected for multiple testing with Benjamini-
Hoghbergs.
Mann Whitney test was used to compare gene
amplification data obtained during real time PCR. Data were
expressed as median and interquartile range.
Statistics were performed with the Statistical Analysis
System software (SAS Institute Inc., North Carolina, USA).
P<0.05 were considered significant.
Results
Patient characteristics (Table 1 and 2)
Hospitalized and stable COPD patients had moderate
to severe airflow obstruction. Patients with an acute
exacerbation had significantly higher CRP levels at
admission and lower quadriceps muscle force compared
to stable COPD patients. In the patients with an acute
exacerbation, quadriceps force decreases on average by
4.4±7% during hospitalization.
Microarray data
Single gene microarray analysis revealed that 1,989
genes were differentially expressed between hospitalized
and stable COPD patients, of which 930 were upregulated
and 1,059 were downregulated. The top 25 of the most
highly upregulated and downregulated genes are provided
in table 4 and 5, respectively.
The multidimensional scaling plot of the principal
component analysis reveals that hospitalized COPD
patients represent a distinct population from stable COPD
patients according to their gene expression.
Gene Ontology analysis (Table 6) revealed that
several transcripts of the ubiquitin-dependent protein
catabolism such as the ubiquitination factor 4A and the
proteasome 26S subunit 5 were upregulated in hospitalized
compared to stable COPD patients. Also transcripts of
apoptosis and anti-apoptosis induction (TNF receptor-
associated factor 3 and CASP8- and FADD-like apoptosis
regulator) were upregulated as were transcripts of the
response to reactive oxygen species namely superoxide
dismutase 2 and glutathione peroxidase 3. In addition,
analysis shows that transcripts of the aspartate catabolism,
specifically the aspartate aminotransferase and the
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aspartoacyclase were downregulated in hospitalized
COPD patients. This was also the case for the two related
ontologies mitochondrial respiratory chain and
oxidoreductase activity acting on NADH or NADPH,
such as the cytochrome c oxidase subunit 6C and the
NADH-ubiquinone oxidoreductase Fe-S protein 1.
According to the GSEA algorithm, transcripts
belonging to proteasomal degradation and the Akt/FoxO
Table 8. David analysis showing the genes being upregulated in the vastus lateralis muscle of hospitalized
compared to stable COPD patients. FDR: False Discovery Rate.
Table 9. David analysis showing the genes being downregulated in the vastus lateralis muscle of
hospitalized compared to stable COPD patients. FDR: False Discovery Rate.
pathways were upregulated while transcripts belonging
to the oxidative phosphorylation pathway were repressed
in the vastus lateralis of hospitalized patients compared
to stable COPD patients (Table 7).
As shown on table 8 and 9, DAVID analysis
confirmed these data although the upregulation of the
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Fig. 1. mRNA expression levels of MURF-1 (A), MAFbx (B)
and COX6C (C) in the vastus lateralis muscle of COPD patients
with an acute exacerbation (EXAC) and stable COPD patients
(STABLE). Data are expressed as copy number per million
copies of 18S and are presented as median and interquartile
range. * p < 0.05.
Real-time PCR data
The proteasomal degradation and Akt/FoxO
pathways as well as the oxidative phosphorylation
pathways were selected for further analysis. MuRF-1
and MAFbx were chosen as key-genes of the proteasomal
degradation pathway. They are both coding for muscle
specific atrophy-related ubiquitin protein ligases. MuRF-
1 and MAFbx mRNA was significantly higher in
hospitalized patients compared to stable COPD patients
(Fig. 1A, and 1B). A 1.5 fold change in FoxO1A mRNA
was found in the hospitalized patients compared to stable
COPD patients while a -4.5 fold changes were found in
FoxO3A mRNA. However, these data did not reach
statistical significance.
COX6C was chosen as marker of the oxidative
phosphorylation pathway as it is coding for a subunit of
cytochrome c oxidase. COX6C mRNA was significantly
lower in hospitalized compared to stable COPD patients
(Fig. 1C). Similarly, mRNA levels of ATP5G2 (encoding
a subunit of mitochondrial ATP synthase) and PET112L
(involved in formation of correctly charged Gln-tRNA )
were downregulated (fold changes: -5.5 and -4.9,
respectively) in hospitalized compared to stable COPD
patients although these alterations failed to reach statistical
significance.
Discussion
The present study showed that in the vastus lateralis
muscle of COPD patients with an acute exacerbation,
the ubiquitin-dependent protein catabolism, the Akt/FoxO
pathway, the induction of apoptosis and anti-apoptosis and
the response to reactive oxygen species are upregulated
while the aspartate catabolism, the oxido reductase activity
acting on NADP-NADPH, the oxidative phosphorylation
and the mitochondrial respiratory chain are downregulated.
Real-time PCR showing increased MuRF1 and MAFbx
mRNA and decreased COX6C mRNA confirmed the
activation of the ubiquitin-dependent protein catabolism
and the downregulation of mitochondrial respiration
pathway.
This study is the first showing that pathways leading
to muscle atrophy are activated in the muscle of COPD
patients during an acute exacerbation. In particular the
ubiquitin-proteasome pathway, the Akt/FoxO pathway but
also molecular triggers (reactive oxygen species, apoptosis
process) are upregulated during exacerbation. In fact,
most of these pathways or processes are already
activated in the muscle of stable COPD patients.
Indeed, a micro-array study has already reported
activation of the ubiquitin-proteasome pathway in the
quadriceps muscle of stable COPD patients compared
to controls [10]. Activation of this pathway is further
evidenced by the increased MuRF1 mRNA and MAFbx
mRNA and protein levels in the quadriceps muscle of
stable COPD patients presenting muscle atrophy [20].
In these patients, the cytoplasmatic protein content of
the phosphorylated form of Akt was also elevated [20]
and FoxO-1 and to a lesser extent FoxO-3 were upregula-
ted [9, 20]. As expected, protein breakdown is increased
in stable COPD patients with low BMI [21]. The data of
the present study revealed that these processes are more
pronounced in the muscle of COPD patients suffering
from an acute exacerbation. This is particularly important
as this may result in enhanced proteolysis leading to a
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impact on muscle function. In fact, these processes are
closely interrelated. The Akt/FoxO pathway is able to
modulate the expression of MuRF1 and MAFbx [22]. In
the absence of IGF-I, the FoxO transcription factors are
dephosphorylated and translocated to the nucleus to drive
the expression of MuRF1 and MAFbx. This is particularly
interesting knowing that muscle IGF-I expression is
decreased in COPD patients with an acute exacerbation
[15]. This suggests that activation of the ubiquitin-
proteasome pathway via the FoxO pathway develops in
the muscle of COPD patients during an acute
exacerbation.
Increase in reactive oxygen species is thought to
reflect damage caused by oxidative stress. Higher
expression of genes involved in oxidative stress has been
reported in the quadriceps muscle of stable COPD patients
compared to controls [10]. In addition, increased levels
of lipid peroxidation [23], protein carbonylation [24] and
hydrogen peroxide [25] have all been reported in the
vastus lateralis muscle of stable COPD at rest. More
recently, direct measurement of ROS production in
mitochondria isolated from the vastus lateralis muscle of
moderate COPD patients showed that ROS are enhanced
at rest in these patients [26]. This means that the oxidative
stress which is already present in the muscle of stable
COPD patients is further exaggerated during an acute
exacerbation as shown in the present study. Excessive
ROS production within the muscle is known to mainly
target mitochondria and myofilaments. This would lead
to apoptosis, mitochondrial respiratory chain dysfunction
and/or alteration in myofilament contractile properties (see
[27] for a review). This is in agreement with the data of
the present study suggesting upregulation of apoptosis
and downregulation of mitochondrial respiration process.
The presence of increased apoptosis namely higher
percentage of apoptotic myonuclei has been reported in
the quadriceps muscle of stable COPD with low BMI in
whom BMI was inversely related to skeletal muscle
apoptosis [28]. In the present study, apoptosis was further
activated during an acute exacerbation. Although apoptosis
leads normally to cell death, it can also cause cell atrophy
especially in multinucleated cells [29]. In skeletal muscle
fibers, each myonucleus regulates the gene products and
protein expression in a limited volume of the muscle fiber.
This volume is termed the myonuclear domain. Decrease
in myonuclear domain through apoptosis has been reported
in several experimental models of muscle atrophy [30].
Also in patients with heart failure, apoptosis, while
measuring the amount of apoptotic nuclei, increased in
the vastus lateralis muscle and the magnitude of apoptosis
was associated with the degree of muscle atrophy [31].
It has, therefore, been proposed that apoptosis might play
a role in determining muscle bulk loss [31]. If so, this
would suggest that apoptosis developing in the muscle of
COPD patients during an acute exacerbation would
probably contribute to muscle wasting. The latter may
affect muscle force and may eventually postpone muscle
recovery in these patients.
The two main signaling pathways of apoptosis are
mediated either through the death receptor family or
through the mitochondrial apoptotic pathway. In the latter,
apoptosis is initiated by the release of cytochrome c from
the mitochondria which forms a complex with the apoptotic
protease activating factor-1 and the pro-caspase-9 leading
to the activation of caspase-9 and caspase-3. Basal
amount of cytochrome c was recently shown to be
elevated in different muscles of stable COPD patients
[26]. In addition, increased levels of cytochrome oxidase
which uses cytochrome c as substrate have been found
in the quadriceps of these patients [32]. Importantly, this
mitochondrial apoptotic pathway is stimulated by reactive
oxygen species [33] and those are upregulated in the
muscle of COPD patients during an acute exacerbation.
Furthermore, IGF-I that is known to eventually exert anti-
apoptotic effects while inhibiting the pro-apoptotic factor,
bad, or the caspase-9 [33] is decreased in serum and
muscle of COPD patients during an acute exacerbation
[14, 15]. This underlines that the role of apoptosis during
an acute exacerbation of COPD should not be neglected.
The present study also revealed that the expression
of several pathways was downregulated during
exacerbation. Those pathways involved the aspartate
catabolism, the oxido reductase activity acting on NADP-
NADPH, the oxidative phosphorylation and the
mitochondrial respiratory chain. In fact, these observations
pointed out that the mitochondrial function is altered since
all these processes are belonging to the mitochondria
system. Indeed, the mitochondrial chain is a set of
metabolic reactions and processes that take place to
convert biochemical energy from nutrients into adenosine
triphosphatase (ATP). Transfer of electron from one
redox reaction to another is catalyzed by oxidoreductases.
Oxidative phosphorylation is the metabolic pathway using
energy released by the oxidation of nutrients to produce
ATP. Aspartate carries reducing equivalents in the malate-
aspartate shuttle. All these processes are altered during
an acute exacerbation. This means that ATP production
is impaired.
Evidence for abnormal mitochondrial function was
already described in the muscle of stable COPD patients.
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Oxidative phosphorylation efficiency was decreased in
the vastus lateralis muscle of stable COPD patients, and
this was even worse in those with low BMI [34]. In
addition, protein levels of uncoupling protein-3 (UCP-3)
were shown to be reduced in the vastus lateralis muscle
of stable COPD patients [35]. This protein, predominantly
expressed in skeletal muscle, uncouples oxidative
phosphorylation from ATP production [36]. It has been
suggested that UCP-3 could play a role in limiting ROS
production since mitochondria from skeletal muscle of
UCP3-deficient mice show an increased ROS production
[37].
The consequences of this abnormal mitochondrial
function are obvious for the muscles. The end result of
mitochondrial dysfunction is the impaired aerobic ATP
production. ATP provides the immediate source of energy
for muscle contraction and for pumping ions to maintain
the muscle fiber plasmalemma in an excitable state during
muscle activity. ATP is also required for many of the usual
muscle functions during and between periods of activity.
Even for relatively brief periods of activity, the muscle
must be able to renew its supply of ATP. In COPD
patients, impaired muscle function is partly due to
mitochondrial dysfunction as described previously. In
addition, the present study suggests that the alterations in
mitochondrial function already present in stable COPD
patients are worsened during an acute exacerbation. This
may contribute to the further deterioration of muscle
function seen during exacerbation and this may
compromise recovery after exacerbation. It is therefore
not surprising that COPD patients after an exacerbation
are weak and inactive. Attention to minimize impaired
mitochondrial function during exacerbation should be
considered.
It is clear that the alterations seen in the muscle of
COPD patients during an acute exacerbation have been
triggered by several factors. Among them, inflammation
related to exacerbation, undernutrition, muscle inactivity
during bed rest and use of systemic corticosteroid are
probably playing an important role. These conditions are
all known to affect the above-mentioned pathways that
are altered during an acute exacerbation. Therefore, one
should consider developing strategies to minimize the loss
in muscle function occurring during an exacerbation. This
could be achieved either while targeting the triggering
factors or by acting on key elements of the altered
pathways. This is particularly important knowing that
muscle function recovers very slowly after an
exacerbation. In some COPD patients with repeated
exacerbations, muscle function may therefore be severely
impaired especially if exacerbation occurs when muscle
did not yet recover from the previous exacerbation.
In conclusion, the present study suggests that several
pathways leading to muscle atrophy and mitochondrial
dysfunction are activated in the muscle of COPD patients
during an acute exacerbation. These alterations potentially
contribute to loss in muscle force described in COPD
patients during an acute exacerbation and would probably
lead to muscle wasting. Therefore, therapeutic
interventions should be designed to counteract the
detrimental effect of exacerbation on these pathways.
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